South Africa boosts HIV funding amid global crisis affecting children and young women
Image: Independent Newspapers Archives
As the world faces a historic HIV funding crisis that threatens to reverse decades of progress, South Africa is emerging as a beacon of commitment, funding 77 percent of its national HIV response and pledging further increases in health and HIV spending over the next three years.
According to UNAIDS' 2025 Global AIDS Update, released last week, South Africa's 2025 budget review includes a 5.9 percent annual increase in overall health expenditure and a 3.3 percent annual rise for HIV and tuberculosis programmes, along with plans to invest in health systems infrastructure, including a national chronic medicine dispensing system.
But the report, titled 'AIDS, Crisis and the Power to Transform', warns that South Africa is an exception in a world where funding cuts are devastating HIV services, particularly for children and young women in low- and middle-income countries.
In 2024, 620,000 children under 15 living with HIV did not receive treatment, leading to 75,000 AIDS-related child deaths. The year also saw 630,000 AIDS-related deaths globally, with 61 percent of them in sub-Saharan Africa.
'This is not just a funding gap: it's a ticking time bomb,' said UNAIDS Executive Director Winnie Byanyima. 'People, especially children and key populations, are being pushed out of care.'
Adolescent girls and young women aged 15 to 24 are being hit especially hard. In 2024, over 210,000 acquired HIV, an average of 570 new infections every day. Prevention programmes that once protected this group are vanishing as donor funding disappears.
Video Player is loading.
Play Video
Play
Unmute
Current Time
0:00
/
Duration
-:-
Loaded :
0%
Stream Type LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text Color White Black Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Transparent Semi-Transparent Opaque
Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps
Reset
restore all settings to the default values Done
Close Modal Dialog
End of dialog window.
Advertisement
Video Player is loading.
Play Video
Play
Unmute
Current Time
0:00
/
Duration
-:-
Loaded :
0%
Stream Type LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text Color White Black Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Transparent Semi-Transparent Opaque
Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps
Reset
restore all settings to the default values Done
Close Modal Dialog
End of dialog window.
Next
Stay
Close ✕
In Nigeria, monthly PrEP (pre-exposure prophylaxis) initiation fell from 40,000 to just 6,000 people, while more than 60 percent of women-led HIV organisations surveyed in early 2025 had lost funding or shut down. In Mozambique, over 30,000 health personnel were affected by funding-related disruptions.
If the crisis continues, UNAIDS estimates 6 million new HIV infections and 4 million AIDS-related deaths could occur between 2025 and 2029.
While 25 countries have pledged domestic increases totalling 180 million US dollars in 2026, UNAIDS warns this is not enough to replace the large-scale donor withdrawals.
Community-led services, crucial for reaching vulnerable populations, are being slashed, while new punitive laws in countries like Uganda and Mali are pushing people further from care.
'There is still time to transform this crisis into an opportunity,' said Byanyima. 'Countries are stepping up with domestic funding. Communities are showing what works. We now need global solidarity to match their courage and resilience.'
'In a time of crisis, the world must choose transformation over retreat,' she added. 'Together, we can still end AIDS as a public health threat by 2030 if we act with urgency, unity, and unwavering commitment.'
THE MERCURY
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Citizen
an hour ago
- The Citizen
Health budget: R1.7 billion for new staff and millions granted by Gates foundation
Health minister Aaron Motsoaledi announced a R64 billion health budget and a R200 million HIV/ Aids research grant from international funders. The department of health plans to spend billions on recruiting new professionals and infrastructure development over the coming financial year. Health Minister Aaron Motsoaledi announced the coming years' objectives during his budget speech in parliament on Tuesday. The minister added that international organisations will plug the gap left in South Africa's HIV/ Aids programmes by the Pepfar decision. He conceded that the department did not have 'all the money' needed to achieve these objectives, but was in discussions with international and local funders. R64 billion budget Motsoaledi announced that the department had been allocated an overall budget of R64 billion for the 2025/26 financial year. The budget will be used by the department to achieve three main objectives; number one being a laying of the foundations for the National Health Insurance (NHI). 'There are people who believe that we have no plans nor inclination to do that. We want them to listen very attentively,' assured Motsoaledi. Ensuring adequate facilities and sufficient staff would be the backbone of NHI, the minister has earmarked R1.7 billion for the hiring 1 200 doctors and 450 nurses and support staff. A further R1.4 billion will be spent on absorbing 27 000 community health workers who had previously been employed by non-governmental organisations. To 'make public hospitals hospitable', R1.3 billion will be spent on beds, linen, towels, basin and other similar items. Infrastructure upgrade During the last financial year, Motsoaledi boasted that 47 existing clinics and 45 hospitals had been 'substantially' refurbished, while 403 public health facilities had been upgraded. Additionally, five new facilities were completed during the last financial year, and six are currently under construction, and 17 are in the design and development stage. 'These facilities and their placement are not a thumbs-up. We are using a digital system called the Health Infrastructure Portfolio System,' explained the minister. 'This digital system has a geographic information system, district information system and other data tools that help us understand and plan the health system,' he added. The department will also spend R3.75 billion paying accruals — expenses recorded but not paid in earlier financial years — for equipment and pharmaceuticals. The second of Motsoaledi's objectives is to implement 'serious reforms' in the private healthcare system — a goal he did not elaborate on. 'Please ignore those who want us to believe that there is nothing to fix in that sector,' he said. Pepfar replacement Third on Motsoaledi's list is the elimination of diseases such as HIV/ Aids, tuberculosis, malaria and some cancers. 'The time has now arrived to start dreaming about a future with a certain disease gone from our country,' Speaking on the impact of the Pepfar withdrawals, he stated the department would not allow South Africa's HIV programmes to collapse. He said negotiations with treasury had resulted in the allocation of R753 million for provincial and national HIV/ Aids-related support. This will be boosted by R100 million research contributions by both The Bill and Melinda Gates Foundation and London-based researchers the Wellcome Trust. The grants are conditional based on Treasury's commitment to double it, meaning the R200 million from the international funders will be backed by R400 million from Treasury, which is to be released more than three years for HIV/ Aids treatment. Part of this treatment will include the piloting of HIV/ Aids wonderdrug Lenacapavir, a twice-annually injection that claims to have a 100% success rate in preventing HIV/ Aids in women. NOW READ: Health minister weaponising racial bias report to push NHI, says IRR
Daily Maverick
13 hours ago
- Daily Maverick
New respiratory virus vaccine a game changer for babies, but cost remains a barrier
A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector, but not yet in public clinics. The country's advisory group on immunisations has recommended making it available to all pregnant women. This proposal is now under review by the national Department of Health. Like the common cold, respiratory syncytial virus (RSV) is highly contagious. It is spread through airborne respiratory droplets and contact with contaminated surfaces. RSV infection is often difficult to distinguish from the common cold. This is because it has similar symptoms and typically clears up without medical intervention. However, in some cases, it can become serious enough to need medical care or even a hospital stay, especially for babies under six months old, who are the most vulnerable. Severe illness typically affects the lower respiratory tract and can lead to bronchiolitis or pneumonia, which can cause difficulty breathing. Babies who are admitted to hospital may need extra help, such as oxygen to help them breathe, fluids through a drip to keep them hydrated, and in serious cases, a machine to help them breathe. RSV is a major cause of illness and death in children under five, especially in the first six months of life in low- and middle-income countries. A recent global study estimated that in 2019, RSV was responsible for just over 100,000 deaths in children under five. This made up 2% of all deaths in this age group, and 3.6% of deaths in babies aged 28 days to six months. Nearly half of all RSV-related deaths occurred in babies under six months, and 97% of these deaths were in low- and middle-income countries. A new vaccine to prevent RSV in infants A new vaccine provides infants with significant protection against severe RSV disease. It is given to pregnant women during their third trimester of pregnancy (from week 28 to birth). Protective antibodies elicited by the vaccine are transferred from the mother to the foetus across the placenta. Currently, only one pharmaceutical company, Pfizer, markets the maternal RSV vaccine. It is sold under the brand name Abrysvo. It is also known by the generic name RSVpreF. The South African Health Products Regulatory Authority approved Abrysvo in December 2024, and it became available in the country's private sector in 2025. The effectiveness of the vaccine in preventing severe RSV disease was first announced in November 2022. This followed early positive results from the Maternal Immunisation Study for Safety and Efficacy (Matisse) which was conducted in 18 countries, including South Africa. It showed that infants born to mothers who received the maternal RSV vaccine had an 82.4% lower risk of developing severe RSV-associated lower respiratory tract illness within the first 90 days of life than infants whose mothers received a placebo. At 180 days after birth, the vaccine was 70% effective in reducing the risk of severe RSV illness. Recommendations from health agencies By September 2023, the United States Centers for Disease Control and Prevention recommended giving the RSV vaccine to pregnant women to help protect their babies from severe illness. One year later, in September 2024, the World Health Organization (WHO) recommended that all countries introduce the maternal RSV vaccine. It also recommended an alternative for babies whose mothers weren't vaccinated: a single dose of the monoclonal antibody nirsevimab, ideally given at birth or before discharge from the birthing facility. While acknowledging cost limitations, the WHO noted that if not given at birth, the antibody could be given at the baby's first health visit. In countries offering it only during RSV season, older infants can receive the dose just before their first season begins. Nirsevimab is not yet registered in South Africa and the cost is expected to be a barrier to its rollout in the country. South Africa has not yet adopted formal guidelines for the broad use of the maternal RSV vaccine. But the National Advisory Group on Immunisations recently recommended that the national Department of Health introduce the RSVpreF vaccine into the public immunisation programme as a single-dose vaccination for all pregnant women. This recommendation was outlined in a letter to Health Minister Dr Aaron Motsoaledi on 23 April 2025. 'In line with the National Advisory Group on Immunisations' terms of reference which govern the committee's work, the department is currently assessing the cost and other implications of RSV vaccine introduction with relevant senior managers and other stakeholders,' the health department's spokesperson, Foster Mohale, told Spotlight. 'Feeback will be provided to the group's chairperson once a decision regarding possible introduction has been reached,' he added. Price remains a barrier Pfizer is selling Abrysvo in South Africa as a single-dose vaccine, priced at R3,746 ($US 210), excluding VAT and dispensing fees. This price for the private sector is significantly higher than the government's threshold for broad roll-out, according to a cost-effectiveness analysis of RSV immunisation. The analysis found that at a price of US$5 (about R90) per dose, the vaccine would offer savings to South Africa's health sector. But if the price exceeds US$40 (about R700) per dose then widespread procurement may no longer be feasible. Pfizer's pricing of Abrysvo in South Africa's private sector is 'disappointingly high', Shabir Madhi, Professor of Vaccinology at the University of the Witwatersrand, told Spotlight. He added that he thought 'something has gone awry in terms of pricing of the vaccine in South Africa'. He pointed out that the Pan American Health Organization, which works to improve the health and quality of life, secured a price of US$49 (about R800) per dose for procurement of the vaccine for use in Latin American countries. 'It does tell us that certainly the cost of producing a vaccine is nowhere close to $200 if the same vaccine is being provided at $49 to the Pan American Health Organization,' said Madhi. Pfizer did not answer questions from Spotlight about whether a lower price would be offered to the public sector, but a company spokesperson said: 'We are committed to working with the government and healthcare stakeholders to ensure our medicines and vaccines are available to all those who need them in South Africa.' 'There has been engagement with Pfizer, and they have indicated that the [public sector] price of the maternal RSV vaccine is likely to align with current Pan American Health Organization pricing,' said Mohale. Apart from pricing, he said that introducing the maternal RSV vaccine involved several other health system considerations. 'A comprehensive implementation guideline will be needed to address areas such as monitoring and evaluation, supply chain capacity, healthcare worker training, and demand creation to ensure effective and sustainable rollout,' said Mohale. Fortunately, South Africa, unlike some other countries, already had established vaccine programmes for pregnant women, said Madhi. 'We've been vaccinating pregnant women with the tetanus vaccine for decades now, and as of last year we actually introduced the acellular pertussis, tetanus, diphtheria combination vaccine for pregnant women,' he said. DM
Daily Maverick
13 hours ago
- Daily Maverick
Slow-motion denialism — our leaders are allowing the HIV response to collapse
South Africa is staging a sequel to Mbeki-era denialism, only this time the science, solutions and costs are clearer. Tragically, we have politicians showing the same disregard for despairing public health experts sounding the alarm and civil society's calls for engagement. Treasury's token contribution, President Cyril Ramaphosa's and the Government of National Unity's (GNU) silence, Deputy President Paul Mashatile's empty promises and Health Minister Dr Aaron Motsoaledi's fabricated success, mean the current child and adult deaths and unnecessary infections are mounting. Exactly six months after the abrupt withdrawal of billions of rands in support to South Africa from the US President's Emergency Plan for Aids Relief (Pepfar), there is still no plan. In May, in response to concerns about HIV service weaknesses, Motsoaledi claimed 520,000 people were initiated on HIV treatment between February and April, a number already almost halfway towards his 'Close the Gap' campaign target. This remarkable success claimed by the minister occurred during a collapse in funding, staffing and testing, and was achieved simply with 'roadshows' and unnamed community programmes. This would represent one of the most remarkable HIV global service delivery achievements yet, given three months of massive funding withdrawal and service collapse. Yet, in the past few weeks: National Health Laboratory Services data shows CD4 test volumes are down sharply from 2024. If more people were entering care, these numbers would rise. This is the clearest indicator we have that far fewer people are entering care. The minister's claim that more than 500,000 people were added to the number on HIV treatment is thus implausible; New data from Johannesburg show HIV diagnoses and people starting treatment are down nearly one-third since Pepfar's withdrawal. In Gauteng, the province with the highest HIV burden, the minister's 520,000 number should be immediately reflected in numbers like these. Yet we are seeing the numbers go down rather than up; Community monitors from Ritshidze – an organisation that monitors the ARV programme – report steep drops in testing, medicine pickups and staff capacity in government facilities offering HIV services. 'Do more with less' is not a realistic strategy to address this; Early infant diagnosis rates have somewhat recovered, too late for many. Infants with HIV have extremely high mortality. These are the bodies behind the pause the minister refuses to call a collapse; A report by Avac, an HIV advocacy organisation, showed most key population programmes have been terminated. 'Key populations' refers to groups at particularly high risk of HIV such as sex workers and men who have sex with men. The government claimed that the patient files from the clinics that provided services to key populations have been transferred to other clinics. But staff at some of the defunded organisations providing these services have told me, despairingly, that key population clinic files now sit, unopened, in overwhelmed clinics; The Clinical HIV Research Unit in Johannesburg shut its cervical cancer screening and prevention clinic in June; and The Global Fund, our significant remaining donor, cut funding to South Africa's current grants by 16%, reducing it by R1.4-billion. The Treasury 'emergency' funding announced last week amounts to roughly half of what the Global Fund cut, and only 6% of the Pepfar cut. Repeated offers of help and pleas for meetings and consultations from local experts and civil society have been ignored by the country's leaders. This includes a letter signed by numerous organisations and individuals from across the country's most respected institutions, setting 7 July as a deadline for a response. Constant promises that the 'plans' for mitigating the HIV programme will be released have not materialised. Reassurances that provinces are getting support is not being experienced by any of the provincial colleagues I speak to. Mashatile has doubled down on the 520,000 number, telling Parliament that the withdrawal of Pepfar funding 'has spurred on' the government to become more 'self-reliant', using BRICS, Lotto and domestic funding to plug the gap, with no details as to how this will happen. He claimed no patient will suffer, despite local studies warning of massive waves of new deaths and infections, multiple anecdotes in the press to the contrary, and submissions by public figures to the Portfolio Committee on Health on service interruptions. Both Mashatile and Motsoaledi have repeatedly lamented, correctly, the severe reliance of our health system on external donors, but have not acknowledged that they have been fully responsible for the health system for almost all of Pepfar's existence. Concerned academics directly responsible for shaping the Department of Health's HIV response, who have called for the minister to explain his 520,000 figure, have not been answered. This crisis is fixable. It requires immediate reinvestment in defunded organisations, the rehiring of experienced managers and an honest medium-term plan for service integration within our health system. None of this is happening. There is no urgency, no leadership and no public plan. Motsoaledi says there is 'no collapse' but patients are dying without diagnosis, and others are acquiring HIV without prevention. Call it what you want. The system is failing. The minister's claims of 'no collapse' ring hollow for the people left stranded with no services, waiting to die for want of a diagnosis and treatment, or unnecessarily contracting HIV for lack of effective prevention. Recent local modelling has shown the Pepfar collapse may result in tens of thousands of preventable deaths, if services are not replaced. The Ramaphosa-Motsoaledi-GNU era risks a ruined legacy, not for failing to stop this crisis, but for pretending it wasn't happening. DM Professor Francois Venter is a clinician researcher at Wits University. He led a large Pepfar programme until 2012 and has had a support role since then. He and his unit do not receive Pepfar, CDC or USAID funding.
